Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEP-Ru salvage therapy for refractory or relapsed hemophagocytic lymphohistiocytosis
ChiCTR1800016124Phase 3Recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Jun 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ruxolitinib, pegylated liposomal doxorubicin, etoposide and methylprednisolone in haemophagocytic lymphohistiocytosis (HLH), sponsored by Beijing Friendship Hospital. Primary endpoints: sCD25, neutrophil and 9 more. Started Jun 2018; status: recruiting.
02
Drugs
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on ChiCTR1800016124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016124.